← Eichor
Condition: Locally Advanced Unresectable Pancreatic Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Locally Advanced Unresectable Pancreatic Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Wi
Phase 3 · 274 location(s) · SWOG Cancer Research Network · NCT06998940Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627711Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
NA · 2 location(s) · BetaGlue Therapeutics SpA · NCT07155850A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal
Phase 1 · 46 location(s) · Astellas Pharma Global Development, Inc. · NCT05365581Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
NA · 1 location(s) · Fox Chase Cancer Center · NCT06984562Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma
Phase 1 · 2 location(s) · Impact Biotech Ltd · NCT05919238A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06261359Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NA · 15 location(s) · Alpha Tau Medical LTD. · NCT06698458Surgery for Locally Unresectable Pancreatic Cancer
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07241663Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Phase 1/Phase 2 · 2 location(s) · Dana-Farber Cancer Institute · NCT04789486Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Phase 3 · 322 location(s) · NRG Oncology · NCT06958328A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Meta
Phase 2 · 1 location(s) · The University of Texas Health Science Center, Houston · NCT06831136PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
Phase N/A · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT05524090A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Astellas Pharma Global Development, Inc. · NCT07488676A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 · 20 location(s) · Astellas Pharma Inc · NCT07094204NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07595172Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT06026943
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.